AC Immune
Swiss biotech company raises CHF 21M in private financing
Published in Pharma Investments, Ventures and Law Weekly, June 12th, 2005
The financing goal of CHF 21 millions was achieved with 2/3 of the invested capital contributed by new investors.
AC immune is focused on new therapies for the treatment of Alzheimer's disease using vaccination or passive immunization with antibodies. Both the active and passive immunotherapy is directed against the beta amyloid protein that misfolds and forms plaques in Alzheimer disease.
The patent-protected antigen technology of AC Immune provides highly efficient immunization and solubilization of the plaques...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- A.P. Pharma, Inc.
Pharmaceutical firm reports loss of $0.05 per share, clinical trial update - Abbott
Sales increase 14% for pharmaceutical company - Acadia Pharmaceuticals, Inc.
Biopharmaceutical company reports first quarter loss of $5.6M - Access Pharmaceuticals, Inc.
Pharmaceutical firm records loss of $0.16 per share - Advancis Pharmaceutical Corporation
Private placement of common equity closed by pharma firm - Aeolus Pharmaceuticals, Inc.
Pharmaceutical company records loss of $0.12 per share, reports on ALS drug - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
